
All active ingredients are made from natural products, The mouth spray's active ingredients UPplus-U ans UPplus-P have anti-bacterial and anti-viral properties which provide enhanced immunity as well as greater lung and throat protection based on long term studies.
Broad Spectrum Application to Fight Against Bacteria and Viruses
UPplus KBD Spray helps reduce occurrence of symptoms of upper respiratory tract infection. The active ingredients UPplus-U ans UPplus-P relieve dry and itchy throat and improve immune defence to promote general health and well-being. It also helps reduce occurrence of symptoms of upper respiratory tract infection, relieves dry and itchy throat and improves immune defence.
Improve Immunity
Promote T cell proliferation, enhance T cell activity, promote IL-2 and IFN-γ secretion, inhibit the expression of interleukin 17 and cell necrosis factor TNFα.
Reduce Lung Function Damage Caused by Air Pollution
Reducing lung function damage caused by air pollution: UPplus-P prevents and alleviates oxidative damage caused by PM2.5, alleviates inflammation and white blood cell count caused by PM2.5.
Kill Dozens of Bacteria
Kill dozens of bacteria: UPplus-U, UPplus-P specifically kill pathogens and drug-resistant pathogens. By destroying the bacterial cell membrane, interfering with the accuracy of bacterial gene transcription, affecting the stability of bacterial messenger RNA, disrupting bacterial sugar metabolism, and ultimately killing bacteria.
Inhibition of Respiratory Viruses
UPplus active ingredients directly inhibit the contact and recognition of viruses and receptors on the surface of respiratory cells. Inhibits proteases necessary for virus replication. UPplus stops the pathological process caused by viral infection by activating the body's immunity.

How does UPplus Work?
Protects Against Air Pollution and Smoking Induced Stress
UPplus-U decreased oxidant stress and cell apoptosis in airway and accompanying vascular walls of cigarette smoking.
UPplus Prevents Air Pollution Induced Function Decline
UPplus-P possess antiviral activities through inhibited virus protease, produces immature and noninfectious virions and molecules, consequently blocking the life cycle of virus.
UPplus-P prevented the lung function decline caused by PM2.5
Reduced the level of oxidative damage in PM2.5-exposed rats.
Inhibited PM2.5-induced inflammation response.
Downregulation of white blood cells in bronchoalveolar lavage fluid (BALF). Downregulation inflammation-related lipids and proinflammation cytokines in lung.
Protect Against Harmful Bacteria
UPplus-U induce: Membrane Disruption; Translation Interruption; Metabolic Pathway Interaction; Oxidative Stress Response
Protects Against Virus
UPplus-U/P possess antiviral activities through inhibited virus protease, produces immature and noninfectious virions and molecules, consequently blocking the life cycle of virus.
Based on the above mentioned study outcomes, UPcare scientists conducted screening, toxicty studies and preclinical trials in order to bring the best natural antiviral medicine to
protect human respiratory health.
For more information, please contact our research team at: enquiries@upcare.tech
References
Khurshid, Z., M. Naseem, M. S. Zafar, S. Najeeb, and S. Zohaib. 2017. 'Propolis: A natural biomaterial for dental and oral healthcare', J Dent Res Dent Clin Dent Prospects, 11: 265-74.
Kim, T. M., K. R. Paudel, and D. W. Kim. 2020. 'Eriobotrya japonica leaf extract attenuates airway inflammation in ovalbumin-induced mice model of asthma', J Ethnopharmacol, 253: 112082.
Maruta, H., and H. He. 2020. 'PAK1-blockers: Potential Therapeutics against COVID-19', Med Drug Discov: 100039.Thosar, N., S. Basak, R. N. Bahadure, and M. Rajurkar. 2013. 'Antimicrobial efficacy of five essential oils against oral pathogens: An in vitro study', Eur J Dent, 7: S071-S77.
Uddin, Z., Y. H. Song, M. J. Curtis-Long, J. Y. Kim, H. J. Yuk, and K. H. Park. 2016. 'Potent bacterial neuraminidase inhibitors, anthraquinone glucosides from Polygonum cuspidatum and their inhibitory mechanism', J Ethnopharmacol, 193: 283-92.
Kommentare